scholarly journals Pain Management for the Cancer Pain by Continuous Intravenous Infusion of Ketamine: A case report

1999 ◽  
Vol 37 (1) ◽  
pp. 168
Author(s):  
Hyun Jung Ahn ◽  
Sang Gon Lee
2015 ◽  
Vol 04 (14) ◽  
pp. 2418-2421
Author(s):  
Upendra Singh K ◽  
Kh. Lokeshwar Singh ◽  
Thoibahenba Singh S ◽  
Charan N ◽  
Jonan Puni Kay

Author(s):  
A Nailufar ◽  
R Muji Laksono ◽  
T Agus Siswagama ◽  
A Andyk Asmoro ◽  
D Rahmat Basuki ◽  
...  

PRILOZI ◽  
2018 ◽  
Vol 39 (2-3) ◽  
pp. 121-126
Author(s):  
Marija Toleska ◽  
Biljana Kuzmanovska ◽  
Andrijan Kartalov ◽  
Mirjana Shosholcheva ◽  
Jasminka Nancheva ◽  
...  

Abstract Opioid free anesthesia (OFA) is deffined as anaesthesiological technique where opioids are not used in the intraoperative period (systemic, neuroaxial or intracavitary). Anaphylaxis caused by opioids (fentanyl) is very rare, and the reaction is presented with hypotension and urticaria. When we have proven allergy to fentanyl, patients’ refusal of placing epidural catheter and refusal of receiving bilateral ultrasound guided transversus abdominis plane block (USG TAPB), we must think of using multimodal nonopioide analgesia. The concept of multimodal balanced analgesia is consisted of giving different analgesic drugs in purpose to change the pathophysiological process which is included in nociception, in way to receive more effective intraoperative analgesia with less adverse effects. This is a case report of a 60-year-old male patient scheduled for laparotomic hemicolectomy, who previously had proven allergy to fentanyl. We have decided to give him an opioid free anaesthesia. Before the induction to anaesthesia, the patient would receive dexamethasone (dexasone) 0.1 mg/kg and paracetamol 1 gr intravenously. The patient was induced into general endotracheal anesthesia according to a standardized protocol, with midazolam 0.04 mg/kg, lidocaine hydrochloride 1 mg/kg, propofol 2 mg/kg and rocuronium bromide 0.6 mg/kg. Anaesthesia was maintained by using sevoflurane MAC 1 in order to maintain mean arterial pressure (MAP) with a value of +/- 20% of the original value. After tracheal intubation, the patient had received ketamine hydrochloride 0.5 mg/kg (or 50 mg ketamine) in bolus intravenously and a continuous intravenous infusion with lidocaine hydrochloride (lidocaine) 2 mg/kg/hr and magnesium sulfate (MgSO4) 1,5 gr/hr. At the end of surgery the continuous intravenous infusion with lidocaine and magnesium sulfate was stopped while the abdominal wall was closed and 2.5 g of metamizole (novalgetol) was given intravenously. VAS score 2 hours after surgery was 6/10 and 1 gr of paracetamol was given and the patient was transferred to the Department. Over the next 3 days, the patient had a VAS score of 4-6/10 and only received paracetamol 3x1g and novalgetol 3x1 gr daily, every four hours.


Chemotherapy ◽  
2019 ◽  
Vol 64 (4) ◽  
pp. 210-214 ◽  
Author(s):  
Nael Alakel ◽  
Sandra Heuschkel ◽  
Ekaterina Balaian ◽  
Christoph Röllig ◽  
Martin Bornhäuser

Background: Pegylated asparaginase may induce prolonged hypertriglyceridemia. To date, there is no standard management of this complication. Here, we present a case report of pegylated asparaginase-induced hypertriglyceridemia and hepatotoxicity successfully treated with continuous intravenous infusion of insulin and heparin. Case Presentation: A 51-year-old male patient with lymphoid blast crisis of chronic myelogenous leukemia was treated with pegylated asparaginase. The patient developed severe hypertriglyceridemia. Supportive therapy with low-fat diet, fibric acids, and omega-3 fatty acids was not successful, and later, the patient developed high-grade hepatotoxicity. Like hypertriglyceridemia-induced pancreatitis, continuous intravenous infusion of insulin and heparin was initiated. The level of triglyceride and cholesterol decreased rapidly within 4 days. Conclusion: In case of severe pegylated asparaginase-induced hypertriglyceridemia, continuous intravenous infusion of insulin and heparin can reduce rapidly and safely the triglyceride level. Controlled trials are needed to address this important issue.


2020 ◽  
pp. 131-134
Author(s):  
Po-Yi Paul Su

Background: Until the continued improvements in cancer diagnosis and treatment, many cancers were once considered terminal illnesses. Opioid-based therapy is frequently utilized from the armamentarium for cancer pain treatment since the immediate goals of acute cancer pain management are focused on alleviating pain severity and improving quality of life during this limited time – despite the risks of chronic opioid therapy. However, now, with an expanding cancer survivor population, we lack guidance and tools to assist health care providers and patients in pivoting the focus of cancer pain management from acute relief toward improving function, rehabilitation, and limiting the long-term adverse effects of pain and opioid therapy. Case Report: Here, we present a case exemplifying the ability of intrathecal drug delivery systems to serve a multitude of roles during the various phases of cancer care: from treating acute cancer-related pain, acting as a tool to wean systemic opioid therapy, to being clinically dormant in situ but ready to serve again in the event of cancer recurrence. Conclusion: Intrthecal drug delivery systems are effective tools in managing acute cancer pain and can also be adapted to help manage chronic pain in cancer survivors. Key words: Cancer pain, intrathecal drug delivery system, intrathecal pump, opioid weaning


2020 ◽  
pp. bmjspcare-2020-002705
Author(s):  
Lana Ferguson ◽  
Stacey Hooper

This case report describes the use of dexmedetomidine for refractory cancer pain management in a patient with significant pelvic disease due to metastatic urothelial cancer. Specifically, the management of increased opioid sensitivity secondary to dexmedetomidine is discussed. Further, the phenomenon of dexmedetomidine withdrawal syndrome and our management of this is addressed.


Sign in / Sign up

Export Citation Format

Share Document